Aortic stenosis

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
5 Unique IMPs
0 Commercial trials
Drug classes (ATC)
V Various (ATC V) 1
C Cardiology (ATC C) 1
— ATC code not specified 1
B Haematology (ATC B) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Antiplatelet / NSAID 1 substance
SGLT2 inhibitor 1 substance
Phase III: 1 Phase II: 2 Phase IV: 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Oslo University Hospital HF Academic
    IMP not specified
    2023-510211-20-00 1 country 2021 n=360
    Ended

Phase II

2 trials
  • Centre Hospitalier Regional Et Universitaire De Brest Academic
    FLUDEOXYGLUCOSE (18F)
    2024-514587-44-00 1 country 2024 n=100
    Recruiting
  • Universitaetsmedizin Goettingen Academic
    SPIRONOLACTONE
    2024-510869-42-00 1 country 2022 n=150
    Ended

Phase IV

2 trials
  • Fundacion Biomedica Galicia Sur Academic
    ACETYLSALICYLIC ACID; TICAGRELOR
    2023-509290-22-00 3 countries 2022 n=1,200
    Recruiting
  • Rigshospitalet Academic
    EMPAGLIFLOZIN
    2023-504731-40-01 1 country 2024 n=206
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Centre Hospitalier Regional Et Universitaire De Brest Academic 1 Phase II 1
Universitaetsmedizin Goettingen Academic 1 Phase II 0
Oslo University Hospital HF Academic 1 Phase III 0
Fundacion Biomedica Galicia Sur Academic 1 Phase IV 1
Rigshospitalet Academic 1 Phase IV 0
New trials by year
2021
1
2022
2
2024
2
← All indication landscapes